在种族和民族多样性队列中比较Stockholm3、血清生物标志物和风险计算器预测前列腺癌:Stockholm3多民族SEPTA试验评估
SEPTA多中心试验(2019-2023)在符合当地前列腺穿刺指南的种族/民族多样性男性中外部验证Stockholm3,纳入2115例数据完整者。主要结局为检出Grade Group≥2癌。Stockholm3的AUC为0.82,优于游离/总PSA比值0.72、PSA密度0.76、ERSPC-4 0.77、PBCG 0.74和PCPT v2 0.78(均P<.001),决策曲线分析显示最高正向净获益,相比游离/总PSA比值可在保持0.95敏感性下减少44%不必要穿刺。
要点
- Stockholm3检测GG≥2前列腺癌的AUC为0.82,优于所有评估的生物标志物和风险计算器(均P<.001)。
- 决策曲线分析显示Stockholm3具有最高正向净获益。
- 相比游离/总PSA比值,Stockholm3可在保持0.95敏感性下减少44%不必要穿刺。
核心结论
- 在多样性人群中,Stockholm3检测GG≥2前列腺癌的表现优于其他常用生物标志物和风险计算器。
研究设计与样本
- SEPTA为多中心试验,在符合当地前列腺穿刺护理指南的种族/民族多样性男性中外部验证Stockholm3(2019-2023年)。
- 共纳入2115例(98%)具有风险计算器和生物标志物完整数据的男性。
- 主要结局为检出Grade Group≥2(GG≥2)前列腺癌。
- 预测因素包括Stockholm3、游离/总PSA比值、PSA密度、欧洲前列腺癌筛查随机研究-4(ERSPC-4)、前列腺活检协作组(PBCG)和前列腺癌预防试验第2版(PCPT v2)风险计算器。
主要发现
- 2115例男性中位年龄63岁(IQR:58-68),中位PSA 6.1 ng/mL(IQR:4.5-9.0),415例(20%)既往前列腺穿刺阴性,356例(17%)穿刺前接受MRI。
- 穿刺结果:良性1200例(56.7%),检出GG1癌307例(14.5%),检出GG≥2癌608例(28.8%)。
- Stockholm3的AUC为0.82,优于游离/总PSA比值0.72、PSA密度0.76、ERSPC-4 0.77、PBCG 0.74和PCPT v2 0.78(均P<.001)。
- 决策曲线分析显示Stockholm3表现更优,具有最高正向净获益。
- 相比游离/总PSA比值,Stockholm3可在保持0.95敏感性下减少44%不必要穿刺。
关键数值与推荐
- Stockholm3检测GG≥2癌的AUC为0.82,游离/总PSA比值0.72,PSA密度0.76,ERSPC-4 0.77,PBCG 0.74,PCPT v2 0.78(均P<.001)。
- Stockholm3相比游离/总PSA比值可减少44%不必要穿刺,同时保持0.95敏感性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to compare performance of Stockholm3 in an external validation with commonly used prostate cancer biomarkers and risk calculators. MATERIALS AND METHODS: SEPTA was a multicenter trial validating Stockholm3 in a racially/ethnically diverse population of men meeting local care guidelines for prostate biopsy (2019-2023). In total, 2115 (98%) men with complete data for risk calculators and biomarkers were included. The primary outcome was detection of Grade Group ≥ 2 (GG ≥ 2) cancer. Predictors included Stockholm3, free/total PSA ratio, PSA density, European Randomized Study of Screening for Prostate Cancer-4, Prostate Biopsy Collaborative Group, and Prostate Cancer Prevention Trial version 2 risk calculators. Performance characteristics were computed at clinically used thresholds for each risk score. ROC analysis, graphical calibration assessment, and decision curve analysis were performed. RESULTS: Among 2115 men, median age was 63 years (IQR: 58-68), median PSA was 6.1 ng/mL (IQR: 4.5-9.0), 415 (20%) had a prior negative prostate biopsy, and 356 (17%) had an MRI performed before biopsy. There were 1200 (56.7%) benign biopsies performed, 307 (14.5%) GG1 cancers detected, and 608 (28.8%) GG ≥ 2 cancers detected. The Stockholm3 test had superior discrimination (all P < .001) compared with all evaluated biomarkers and risk calculators with an AUC of 0.82 vs 0.72 for free/total PSA, 0.76 for PSA density, 0.77 for European Randomized Study of Screening for Prostate Cancer-4, 0.74 for Prostate Biopsy Collaborative Group, and 0.78 for Prostate Cancer Prevention Trial version 2. Decision curve analysis demonstrated superior performance of Stockholm3, showing the highest positive net benefit. Compared with free/total PSA, Stockholm3 could reduce unnecessary biopsies by 44% while maintaining a 0.95 sensitivity. CONCLUSIONS: Stockholm3 outperforms other commonly used biomarkers and risk calculators for detecting GG ≥ 2 cancer in a diverse population.
引用
- Lazarovich A, Vigneswaran H, Palsdottir T, et al. A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025. PMID: 40202133. doi:10.1097/JU.0000000000004437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。